Reported 5,319 shares, down 547 (9.3%) from the prior quarter.
Reported value -21.6%; share count -9.3% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2023-06-30 | 6396 |
| 2023-09-30 | 13414 |
| 2023-12-31 | 100610 |
| 2024-03-31 | 113304 |
| 2024-06-30 | 20414 |
| 2024-09-30 | 16010 |
| 2024-12-31 | 50421 |
| 2025-03-31 | 128213 |
| 2025-06-30 | 24294 |
| 2025-09-30 | 97746 |
| 2025-12-31 | 8378 |
| 2026-03-31 | 0 |
| 2026-06-30 | 67 |
| 2026-09-30 | 41 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Reduced | 132 | -166 (-55.7%) | < 0.01% | $41 | 2026-11-13 | |
| Q2 2026 | New | 298 | +298 (0.0%) | < 0.01% | $67 | 2026-08-13 | |
| Q1 2026 | Reduced | 0 | -12,658 (-100.0%) | 0 | $0 | 2026-05-15 | |
| Q4 2025 | Reduced | 12,658 | -14,876 (-54.0%) | < 0.01% | $8,378 | 2026-02-13 | |
| Q3 2025 | Added | 27,534 | +15,387 (126.7%) | < 0.01% | $97,746 | 2025-11-14 | |
| Q2 2025 | Reduced | 12,147 | -39,138 (-76.3%) | < 0.01% | $24,294 | 2025-08-15 | |
| Q1 2025 | Added | 51,285 | +34,193 (200.1%) | < 0.01% | $128,213 | 2025-05-15 | |
| Q4 2024 | Added | 17,092 | +11,773 (221.3%) | < 0.01% | $50,421 | 2025-02-14 | |
| Q3 2024 | Reduced | 5,319 | -547 (-9.3%) | < 0.01% | $16,010 | 2024-11-14 | |
| Q2 2024 | Reduced | 5,866 | -15,593 (-72.7%) | < 0.01% | $20,414 | 2024-08-14 | |
| Q1 2024 | Added | 21,459 | +1,885 (9.6%) | < 0.01% | $113,304 | 2024-05-15 | |
| Q4 2023 | Added | 19,574 | +17,014 (664.6%) | < 0.01% | $100,610 | 2024-02-13 | |
| Q3 2023 | Reduced | 2,560 | -860 (-25.1%) | < 0.01% | $13,414 | 2023-11-15 | |
| Q2 2023 | New | 3,420 | +3,420 (0.0%) | < 0.01% | $6,396 | 2023-08-14 |
Who else reported the position
51 managers reported VISTAGEN THERAPEUTICS INC COM for Q3 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| TCG Crossover Management LLC | New | 2,676,580 | +2,676,580 | 0.68% | $8,056,505 | 1 qtr |
| BVF INC IL | Unchanged | 2,000,000 | 0 | 0.18% | $6,020,000 | 4 qtrs |
| VANGUARD GROUP INC | Unchanged | 1,793,166 | 0 | < 0.01% | $5,397,430 | 6 qtrs |
| STEMPOINT CAPITAL LP | Reduced | 1,846,792 | -1,790 | 1.47% | $4,900,565 | 4 qtrs |
| COMMODORE CAPITAL LP | Unchanged | 1,575,000 | 0 | 0.3% | $4,740,750 | 5 qtrs |
| Nantahala Capital Management LLC | Unchanged | 1,517,696 | 0 | 0.23% | $4,568,265 | 4 qtrs |
| SPHERA FUNDS MANAGEMENT LTD | Unchanged | 808,550 | 0 | 0.39% | $2,433,736 | 5 qtrs |
| GREAT POINT PARTNERS LLC | Reduced | 674,075 | -855,263 | 0.6% | $2,028,966 | 4 qtrs |
| BlackRock Inc | New | 412,129 | +412,129 | < 0.01% | $1,240,509 | 1 qtr |
| CITADEL ADVISORS LLC | Reduced | 321,885 | -307,760 | < 0.01% | $968,874 | 6 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2024
- Filed
- November 14, 2024
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 4,902
- Shared
- 0
- None
- 417
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.